NCT06357754Recruiting
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Protocol for Transgene Assay Service
Source: ClinicalTrials.gov · Last updated 22 Jan 2026
Brief summary (registry, in English)
The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 4 Apr 2024
- Start date
- 6 Oct 2023
- Primary completion date
- 6 Oct 2038
- Lead sponsor
- Bristol-Myers Squibb
- NCT number
- NCT06357754
What you commit to
- Study type: Observational
- Planned participants: 50
- From 6 Oct 2023 to the primary completion date, 6 Oct 2038
- 8 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participant has not received a BMS manufactured GMCT or has not been diagnosed with a qualifying second primary malignancy.
Other
- Participant is actively participating in a clinical trial where information and sample collection is being conducted under that clinical trial.
Who the study is looking for
- Participant has received a commercially available Bristol-Myers Squibb (BMS) manufactured Gene Modified Cell Therapy (GMCT) and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which BMS has qualified for testing.
- Participant has received a commercially available BMS manufactured GMCT in a clinical trial or other investigational setting (including non-conforming product) for which there is no testing protocol in place for that trial or investigational setting and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which BMS has qualified for testing.
Sex: All
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kantonsspital Aarau Coordinator of this site? Confirm its status | Aarau | Switzerland | Recruiting |
| Universitaetsklinikum Essen (AoR) Coordinator of this site? Confirm its status | Essen | Germany | Recruiting |
| Local Institution - 0003 Coordinator of this site? Confirm its status | Kumamoto | Japan | Withdrawn |
| Toyokawa City Hospital Coordinator of this site? Confirm its status | Toyokawa | Japan | Recruiting |
| UT Southwestern Coordinator of this site? Confirm its status | Dallas | United States | Recruiting |
| Local Institution - 0004 Coordinator of this site? Confirm its status | Madison | United States | Withdrawn |
| Local Institution - 0016 Coordinator of this site? Confirm its status | Portland | United States | Not yet recruiting |
| Huntsman Cancer Institute at the University of Utah Coordinator of this site? Confirm its status | Salt Lake City | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.